CURRICULUM VITAE

Gregory G Allen, Jr., D.O.

Medical License Rhode Island # DO 00582
Medical License Massachusetts # 237829

Employment

Attending Physician — 2005-Present
Roger Williams Medical Center
825 Chalkstone Ave, Providence, RI 02908

Division Director, General Internal Medicine — January, 2014-Present
Roger Williams Medical Center
825 Chalkstone Ave, Providence, RI

Director, Inpatient Clinical Clerkships — January, 2014-Present
Roger Williams Medical Center
825 Chalkstone Ave, Providence, RI 02908

Primary Care Physician
Ocean State Primary Care of East Greenwich — August, 2017-present
4300 Post Road, East Greenwich, RI 02818

Medicine Faculty Partners — October, 2012-August, 2017
1407 South County Trail, Suite 432, East Greenwich, RI 02818

Knightsville Internal Medicine — July, 2005-October, 2012
1681 Cranston Street, Suite D, Cranston, RI 02920

Medical Director — March, 2008-October, 2013
Elmhurst Extended Care
50 Maude Street, Providence, RI 02908

Clinical Trial Investigator
Center for Medical Research, LLC — 2013 – Present
50 Maude Street, Providence, RI 02908

NECCR Fall River, LLC — 2009 - 2017
1565 North Main Street, Suite 506, Fall River, MA 02720

NECCR Internal Medicine & Cardiology Associates, LLC — 2009 - 2016
1565 North Main Street, Suites 301 & 306, Fall River, MA 02720

NECCR of Massachusetts, LLC
484 Highland Ave, Fall River, MA 02720 — 2012 - 2016
52-60 Brigham Street, New Bedford, MA 02740 — 2009 - 2012

New England Center for Clinical Research, Inc — 2005 –2012
1681 Cranston Street, Suite C, Cranston, RI 02920

Post-Graduate Training

Roger Williams Medical Center, Providence, RI — August, 2002 - July, 2005
Boston University School of Medicine
Internal Medicine, Categorical Residency

Post-Graduate Education

Doctor of Osteopathic Medicine — June, 2002
University of New England, Biddeford, Maine
College of Osteopathic Medicine

Undergraduate Education

Bachelor of Arts (Magna Cum Laude) — May, 1997
Providence College, Providence, RI

National Board Certification

American Board of Internal Medicine — thru 2027

CURRICULUM VITAE

Gregory G Allen, Jr., D.O.

Medical License Rhode Island # DO 00582
Medical License Massachusetts # 237829

Licenses / Certifications

Licensed Physician (full), State of Rhode Island	thru 2019
Licensed Physician (full), Massachusetts	thru 2021
Controlled Substance Registration	thru 2019
Advanced Care & Life Support (ACLS)	1987 - 2015
Basic Life Support (BLS)	1981 - Present

Previous Employment

Town of North Kingstown, Fire Department North Kingstown, R.I.	1987 - 1998
Rescue Lieutenant	1991 - 1998

Professional Affiliations

R.I. Office of Health Insurance Commissioner Advisory Counsel	2010 - 2017
American College of Physicians-Member	2008 - Present
R.I. Department of Human Services Medicaid, Pharmacy & Therapeutics Committee	2007 - Present
RI Department of Health Tertiary Care Committee Member	2007 - Present
RI Department of Health Osteopathic Physician Representative Primary Care Physicians Advisory Counsel	2006 - Present
R. I. Society of Osteopathic Physicians & Surgeons, Board of Trustees President (2016-Present)	1998- Present
American Osteopathic Society National Delegate (2016-present)	1998 – Present
American Medical Association	1998 – Present
International Association of Firefighters, Local 1651 President (1993-1998)	1987-1998

Leadership Activities

Board of Trustees Tokwotton on the Waterfront	2018-present
Board of Trustees Prospect Provider Group of RI (IPA)	2016-present
Board of Trustees Prospect Provider Group (Next Gen ACO)	2017-present
Assistant Professor, Internal Medicine UNE, College of Osteopathic Medicine	2015 - Present
Adjunct Clinical Assistant Professor of Medicine Boston University School of Medicine	2017-present
Medical Executive Committee Roger Williams Medical Center Chair 2015-2017 Vice President 2017-present	2014 – Present

Leadership Activities (continued)

Clinical Events Variance Committee (Peer Review)	2014-present
Credentials Committee Roger Williams Medical Center	2005-present
Chair, Residents' Council Roger Williams Medical Center	2003 - 2004
President, Class of 2002 UNE, College of Osteopathic Medicine	1998 - 2002

Research Experience

2005

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of XXX XX MG Once Daily and X.XXMG Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.

A Confirmatory Safety and Efficacy Evaluation of 4 Different XXX Treatments in Adult Subjects.

A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of XXX in Obese patients.

A 12 week Double-Blind, Parallel-Group, Placebo- and Active-Controlled Trial to Evaluate the Efficacy and Safety of XXXXXX delivered by XXXXXX in the treatment of Patients with Chronic Obstructive Pulmonary Disease.

A Randomized, Double-Blinded, Parallel Group, Multi-Center Study of XXXXXX vs. XXXXXX for the treatment of Community Acquired Pneumonia.

An 8-week randomized, double-blind, parallel group, multi-center placebo and active controlled dose escalation study to evaluate the efficacy and safety of XXXXX administered alone and in combination with XXXXXX in patients with hypertension.

2006

A Multicenter, Double-Blind, randomized, Placebo-and Active-Controlled, Parallel-Group, Dose Ranging Study of XXXXX in Patients with Overactive Bladder

A Multicenter randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of XXXXXX and XXXXX Combination Therapy in Subjects with Mixed Dyslipidemia.

A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.

A randomized, double-blind, parallel-group, multi-center study of EDP-420 versus Telithromycin for the treatment of Community Acquired Pneumonia.

A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen

A Phase 3, Open-label Period Followed by a Randomized, Double-blind, Placebo-controlled Study of the Analgesic Efficacy and Safety of Extended-release Hyrdocodone/Acetaminophen (Vicodin CR) Compared to placebo in Subjects with Chronic Low Back Pain

A Phase 3, randomized, multi-center, double-blind study comparing the analgesic efficacy of extended release Hydrocodone/Acetaminophen (Vicodin CR) to Placebo in subjects with Osteoarthritis.

A Prospective, Multi-center, Open-Label Study to Evaluate the Safety and Efficacy of the 28-day Oral Contraceptive DR-1021

A 54-Week, Open-Label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/valsartan 320mg in patients with essential hypertension

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to compare the effect of 24 Treatment with Vildagliptin 100mg

qd to Placebo as Add-On Therapy in Patients with Type 2 Inadequately Controlled with Metformin Monotherapy.

A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Subjects with a History of Herpes Zoster.

Effect of Roflumilast on exacerbation rate in patients with COPD. A 52 Week, double-blind study with 500mcg xxxxx once daily versus placebo.

2007

A 36 Week randomized, double-blind, parallel-group, multicenter, active-controlled, optional titration study comparing an xxxxxn-based regimen to xxxxxxxx-based regimen in patients ≥65 years old with Systolic Essential Hypertension.

A 16-week double-blind, randomized, multicenter, forced-titration study to evaluate the antihypertensive efficacy of xxxxxxxxx therapy compared to xxxxxx based therapy in obese, hypertensive patients

A double-blind, multicenter, randomized, parallel-group, yearlong study to assess the efficacy and safety of 0, 800 or 1600mg/day of xxxxxx Administered orally once daily with a reduced calorie diet in obese males and females.

A Phase II, multicenter, randomized, double-mask, placebo-controlled study to evaluate the efficacy and safety of intramuscular xxxxxxxx in subjects with uncomplicated Acute Influenza.

A randomized, multicenter, double-blind, double-dummy, parallel-group study of acetaminophen or xxxxxx compared to placebo on the transient post-dose Symptoms (PDS) following an I.V. infusion of a single dose of xxxxxx 5mg, in post-menopausal women with low bone mass.

A 26 week treatment, multicenter, randomized, double-blind, double-dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of xxxxxxx (selected from 75, 150, 300 & 600 ug o.d.) in patients with chronic obstructive pulmonary disease using blinded xxxxxx (12 ug b.i.d.) and open label xxxxxx (18 ug o.d.) as active controls.

A phase 3b, double-Blind, randomized study to determine the efficacy and safety of xxxxxxxxx Monotherapy and to xxxxxxxx Fixed-dose combination therapy compared to xxxxxx monotherapy and to xxxxx monotherapy in the treatment of subjects with Type 2 Diabetes.

A Phase 3, randomized, multicenter, double-blind, allopurinol-controlled study assessing the efficacy and safety of oral xxxxxx in subjects with Gout.

A randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of xxxxx for the prevention of recurrent, symptomatic Atrial Fibrillation

A confirmatory safety and efficacy evaluation of 2 different Bisacodyl treatments in adult subjects

A randomized, double-blind, parallel-group, multicenter, Phase III study to assess the effect of xxxxxxxxxx 20 and 40 mg OD versus placebo on the occurrence of Peptic Ulcers during 26 weeks in subjects on continuous low-dose xxxxxxxxx xxxxxxxx and xxxxxxxx combination tablet in a TID regimen compared to a BID regimen and BID xxxxxxxx in subjects with Type 2 Diabetes: A 26 week, open-label, multicenter, randomized, parallel group trial to investigate efficacy and safety.

A 12 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a xxxxxxxxxxx flexible dose regimen in patients with overactive bladder

A randomized, double-blind, active-controlled, multicenter, parallel-group, dose-ranging study assessing the safety and efficacy of xxxxxx versus xxxxxxxxxx among patients with an acute episode of Herpes Zoster

A 52-Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Assess the Safety and Efficacy of a 12-Week Treatment of Acute Diverticulitis With xxxxx® 2.4 g/day, Followed by a 9-Month Treatment-free Observation Period"

A Multi-center, randomized, double-blind, placebo-controlled study with an open-label run-in to assess the efficacy, tolerability, and safety of xxx xx or xxxx xx compared to placebo in Opioid-naïve subjects with moderate to severe, chronic pain due to Osteoarthritis of the Knee

A Multi-center, randomized, double-blind, placebo-controlled study with an open-label run-in to assess the efficacy, tolerability, and safety of xxxx10 or xxxx20 compared to placebo in Opioid-naïve subjects with moderate to severe Chronic Low Back Pain

A randomized, open-label, parallel ARM study to investigate the role of the excipients in the xxxxxxx (registered) formulation to mediate changes in lung function

A multi-center, long term, open-label study of xxxxxxxxxxx administered once daily in patients with Fibromyalgia

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of xxx-xxx when co-administered with xxxxxxxxxxxx in subjects with essential hypertension

2008

The Efficacy and Safety of xxx-xxx in the Treatment of Osteoarthritis of the Knee: Pivotal Study I (with PK assessments)

Validation of patient reported outcome measures for the assessment of GERD symptoms and their subsequent impact on patients with a partial response to PPI treatment in a two part multi-center phase IIA study including a four week randomized, double-blind, placebo-controlled parallel-group treatment phase with xxxxxxx, 65 mg bid as add-on treatment to a PPI

A Phase II, Randomized, placebo-controlled Study of xxx-xxxx in patients with Chronic Idiopathic Constipation

A randomized, double-blind, double-dummy, parallel group, Phase 3 efficacy and safety study of xxx-xxxx compared with xxxxxxxxxxx to reduce upper gastrointestinal events including bleeding and symptomatic ulcer disease

A randomized, double-blind,parallel group study evaluating the efficacy and safety of co-administration of a triple combination therapy of xxxxxxxx , xxxxxxxx and xxxxxxxxxxxxx in subjects with hypertension

A Phase II, Multicenter, Randomized, Placebo-Controlled Study to Evaluate The Efficacy and Safety of Intramuscular xxxxxxxx 600 mg In Subjects with Uncomplicated Acute Influenza

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of xxx-xxx in Subjects with Acute Shoulder Pain

A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of xxxxxx xxxxxxxx Compared to xxxxxxxxx in Subjects with Type 2 Diabetes

An 8-week randomized, double-blind, parallel- group, multi-center, active-controlled dose escalation study to evaluate the efficacy and safety of xxxxxxx xxxx (300/25 mg) compared to xxxxxxxxx (10 mg) in patients with stage 2 systolic hypertension and diabetes mellitus

A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of xxxxxxx (150 and 300 µg o.d.) in patients with chronic obstructive pulmonary disease

A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of xxxxxxxxx modified release (MR) as monotherapy in patients with type 2 diabetes

Phase II Randomized, Double-Blind, Placebo and Active Controlled, Multicenter, Parallel Group Proof of Concept Study of the Analgesic Effects of xxxxxx in Adult Patients with Chronic Low Back Pain

A multicenter, randomized, placebo-controlled, "factorial" design, 12-month study to evaluate the efficacy and safety of xxxxxxx 25 mg/day and 50 mg/day co-administered with all registered xxxxxxxxx strengths ranging from 10 mg to 80 mg in patients with primary hypercholesterolemia

2009

A Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a xxxxxxxxx xxxxxx Patch for the Topical Treatment of Acute Pain due to Mild to Moderate Soft Tissue Injuries

A randomized, double-blind, active-controlled, multi-center, parallel-group dose-ranging study assessing the safety and Efficacy of xxx-xxx versus xxxxxxxxx among immunocompetent patients with an acute episode of herpes zoster (the "Study")

A Randomized, Double-Blind, Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effects of xxxxxxxxxxx in Adult Patients with Chronic Low Back Pain

A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either xxxxxxxxx or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

A 12-Month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of xxxxxxxx in Subjects Who Are at Risk for Developing Aspirin-associated Gastric Ulcers

A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of xxxxxxxx compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with xxxxxxx plus xxxxxxxxxx.

A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous xxxxxxxx with oral adjusted-dose xxxxxx in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation

Open-Label Extension (OLE) Safety and Efficacy Study of xxxxxx Following the Year-Long Controlled Clinical Trials of xxxxxx

in Obese Males and Females

A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Determine the Efficacy and Safety of xxxxxxx in Subjects with Type 2 Diabetes

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the xxx-xxx Plus xxxxxxxxx Fixed-Dose Combination vs xxxxxxx® in Subjects With Moderate to Severe Essential Hypertension

A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the xxx-xxx Plus Chlorthalidone Fixed-Dose Combination vs xxxxxxxxxxxx in Subjects With Moderate to Severe Hypertension

An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous xxx-xxx for Treatment of Opioid-Induced Constipation in Subjects with Nonmalignant Pain

A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of xxxxxxxx As Add-on Therapy in High Risk Hypercholesterolemic Patients

Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety and Efficacy of xxxxxxxx/xxxxxxxxx Vaginal Cream in the Treatment of Mixed Bacterial Vaginosis/Vulvovaginal Candidiasis Infections

Clinical Investigation to Evaluate the Performance of the OraQuick® Rapid HCV Antibody Test in Whole Blood

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome

2010

A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5µg and 5µg xxxxxxxxxx Inhalation Solution delivered by the xxxxxxxx ® Inhaler with xxxxxxxxx inhalation capsules 18µg delivered by the xxxxxxxxx®

A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled, Safety Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus Treated With xxxxxxxxxx

A Randomized, Double-Blind, Parallel, Multicenter Study to Evaluate the Efficacy and Safety of Co-administration of xxxxxxxx and xxxxxxxxxx (10/10 mg, 10/20 mg, 10/40 mg and 10/80 mg) versus xxxxxxxxx (5 mg, 10 mg, 20 mg and 40 mg) in Patients with Primary Hypercholesterolemia

A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy and Safety of xxxxxxxxx/xxxxxxxxxx 10 mg/20 mg Fixed-Dose Combination Tablet Compared to Co-administration of Marketed xxxxxxx 10 mg and xxxxxxxx 20 mg in Patients with Primary Hypercholesterolemia

A Randomized, Multicenter, Long Term Study of the Safety of xxxxxxx in Patients with Chronic Low Back Pain

Randomized, double-blind, placebo-controlled study of the effect of a single injection of xxxxxxxxx on reduction of pain from chronic pancreatitis

A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of xxx-xxx in Subjects with Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of xxxxxxx Versus Placebo in Joint Damage in Hyperuricemic Subjects with Early Gout

A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of xxxxxxxxx and xxxxxxx in Subjects With Gout and Cardiovascular Comorbidities

A Randomized Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Tolerability and Safety of xxxxxxx xxxxxxx Controlled- Release Capsules in Opioid-experienced Subjects with Moderate to Severe Chronic Low Back Pain

A Long-Term Open-Label Safety Study of Xxxxxxxxx Xxxxxxxxx Controlled-Release Capsules with Flexible Dosing to Treat Subjects with Moderate to Severe Chronic Pain

A Randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5µg and 5µ xxxxxxxxx delivered by the xxxxxxxx® Inhaler with xxxxxxxx Inhalation capsules 18µg delivered by the xxxxxx®

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of xxxxxxx in Patients with Type 2 Diabetes Mellitus on Background Treatment with xxxxxxx with or without xxxxxxxx

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of xxxxxxxxx in

Patients with Type 2 Diabetes Mellitus on Background Treatment with xxxxxxxxx

A Phase III, Multicenter, Double-Blind, Active-Controlled, 52-Week Extension Study to Evaluate the Safety and Efficacy of xxxxxxx in Patients with Type 2 Diabetes Mellitus Receiving Background Treatment With xxxxxxxxx Alone or in Combination With xxxxxxxxx or With xxxxxxxxxx Alone

A Phase 3B, Multi-Center, Randomized, Double-Blind Study of xxxxxxxxxxxx xxxxxxxxxx Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women with a Previous Singleton Spontaneous Preterm Delivery

A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous xxxxx xxxxxxxxx (FCM) in Patients with Iron Deficiency Anemia (IDA)

A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Safety Study to Evaluate Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Treated with xxxxxxxx Compared to xxxxxxxxx

A 24-Week Study to Evaluate the Efficacy and Safety of xxxxxxx xxxxxxxxx /xxxxxxxx Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

A 52-week efficacy and safety study to compare the effect of three dosage strengths of xxxxxxxx xxxxxxx/xxxxxxx Inhalation Powder with xxxxxxxx on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment

A Randomized, Double-Blind, parallel, Multicenter Study to Evaluate the Efficacy and Safety of Co-administration of xxxxx and xxxxxxx (10/10 mg, 10/20 mg and 10/80 mg) versus xxxxxxx (5 mg, 10 mg,20 mg, and 40 mg) in patients with Primary Hypercholesterolemia

A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy and Safety of xxxxxx/xxxxxxxx 10 mg/20 mg Fixed-Dose Combination Tablet Compared to Co-administration of Marketed xxxxxxxx 10 mg and xxxxxxx 20 mg in Patients with Primary Hypercholesterolemia

An Investigation of Safety and Efficacy of Oral xxxx Tablets on Patients Diagnosed with the Common Cold

A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral xxx-xxx Compared to Oral xxxxxxxx in the Treatment of Patients with Community-Acquired Bacterial Pneumonia

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of xxxxx vs. xxxxxx in Patients with Herpes Zoster

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of xxxxx in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control with Metformin Therapy

XXXX Effectiveness Study: An Investigation of Safety and Efficacy of Oral XXXX Tablets on Patients Diagnosed with the Common Cold

2011

A Clinical Outcomes Study to compare the effect of Xxxxxxx Xxxxxxx/Xxxxxxx Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease.

A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of xxxxxxxx versus xxxxxxxx in patients with type 2 diabetes mellitus at high cardiovascular risk

Prospective Collection of Female First-catch Urine, Vaginal Swab, Endocervical Swab, and Cervical Specimens for Testing With the XXXXXXX Trichomonas vaginalis Assay

A 14 week randomized parallel group placebo-controlled double-blind multicentre study of xxxxxxxxxx 8 mg in overactive bladder patients with sub-optimal response to xxxxxxxx 4 mg er

A long-term, randomized, study of the safety and tolerability of a fixed-dose combination of xxxxxxxx xxxxxxxx/xxxxxxx xxxxxxx compared with xxxxxxx xxxxxxx in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD)

A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of xxxxxxxx xxxxx/xxxxx xxxxxxx Compared With xxxxxxx xxxxxxxx, xxxxxxxx xxxxxxxx and Placebo for 24-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy and Safety of xxxxxx/xxxxxxxxx 10 mg/20 mg Fixed-Dose Combination Tablet Compared to Co-administration of Marketed xxxxxxxxx 10 mg and xxxxxxxxx 20 mg in Patients with Primary Hypercholesterolemia

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Xxxxxxxx/Xxxxxxxx Controlled-release Tablets to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Xxxxxxxx Controlled-release Tablets) in Opioid-experienced Subjects with Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Xxxxxxx/Xxxxxxxx Controlled-release Tablets to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Xxxxxxx Controlled-release Tablets) in Opioid-experienced Subjects with Controlled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the clock Opioid Therapy

A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Xxxxxxxx in Patients with Chronic Idiopathic Constipation

2012

A Safety and Efficacy Study of Inhaled xxxxxxxxx xxxxxxx/xxxxxxxxxxx Combination versus Inhaled xxxxxxxx xxxxxxxxx in the Treatment of Adolescent and Adult Subjects with Asthma

Cross-sectional, Observational Study to Evaluate COPD Severity Using Spirometry and Physician and Patient Assessments

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of xxxx XXX in Patients with Type 2 Diabetes

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Xxxxxxx/Xxxxxxxx When Added to Ongoing Lipid-Modifying Therapy in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

An Evaluation Of The Burden Of Illness Among Adults In The United States With Peripheral And Central Neuropathic Pain

A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study To Assess The Safety And Efficacy Of Xxxxxxxxxxx In Patients With Chronic Idiopathic Constipation

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Xxxxxxxxxx in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome

A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of XXX-xxxxxxxxx in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

A Phase 3B Study To Evaluate the Potential of Xxxxxxxxx to Reduce Cardiovascular Risk in Patients with Stable Cardiovascular Disease and Glucose Abnormalities

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Xxxxxx and Xxxxxx® in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycemic Drugs with a 6-month Safety Extension Period

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of XXX-XXX, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events

2013

A Phase III Trial To Confirm The Anti-Anginal Effect Of XXX In Patients With Stable Angina

A Study to Compare Analyte levels in Blood Samples Collected Using the XXXXX-X Device With Results Obtained by Fingerstick Using the XXXX-X XXXX Capillary Blood Collection System.

A Phase 3, Open-Label, Long-Term Study to Evaluate the Safety, Tolerability and Analgesic Efficacy of XXXX Buprenorphine in Subjects with Moderate to Severe Chronic Pain Requiring Continuous Around-The-Clock Opioid Analgesia for an Extended Period of Time

A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study To Evaluate The Efficacy And Safety Of Lesinurad And Allopurinol Compared To Allopurinol Alone In Subjects With Gout Who Have Had An Inadequate Hypouricemic Response To Standard Of Care Allopurinol

A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study To Evaluate The Efficacy And Safety Of Lesinurad And Febuxostat Compared To Febuxostat Alone At Lowering Serum Uric Acid And Resolving Tophi In Subjects With Tophaceous Gout

An Open-Label Multi-Center Sub-Study To Evaluate The Efficacy, Safety And Tolerability Of XXXX XXX In Patients With Type 2 Diabetes With High Baseline Hba1c

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (XXX-XXXXX) at 30 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

A Phase III Multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of XX (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia

A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of XXXX-XXX in Patients with Mild to Moderate Active Ulcerative Colitis

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-term Use of Xxxxxxxxxx ® (formoterol fumarate) Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma

A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy of XXXXXX Nasal Spray Formulation in Patients with Nocturia

A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Xxxxxxxxxx for the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin

2014

A Safety and Efficacy Study of Inhaled xxxxxxxx xxxxxxxxxx/ xxxxxxxxx Combination versus Inhaled xxxxxxxxx Propionate in the Treatment of Adolescent and Adult Subjects with Asthma

A 6-month safety and benefit study of inhaled xxxxxxxx xxxxxxxxxx/ xxxxxxxxx combination versus inhaled xxxxxxxxxx propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with XX-XXXX in Subjects with Type 2 Diabetes Mellitus

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-term Use of Xxxxxxxxx ® (xxxxxxxxx xxxxxxxx) Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

A Phase 4, Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing xxxxxxxx With xxxxxxx and Ibuprofen Diagnosing Adverse Drug Reactions Registry

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of XXXX XX (xxxxxxxxx), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF-alpha Therapy

A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of xxxxxxxxx in Combination with xxxxxxxxx in Treatment-Naïve and -Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis

A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of xxxxxxxxx in Combination with xxxxxxxxx in Treatment-Naïve or -Experienced Subjects with Chronic Genotype 1

Hepatitis C Virus Infection and Cirrhosis

A 12-Week Phase Ii Study To Evaluate The Efficacy And Safety Of xxx-xxxx Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (Copd) By Targeting The Ship1 Pathway

A Phase 3 Randomized, Double-Blind Study Assessing The Efficacy And Safety Of xx-xxxxxxx And xxxxxxxxx In Combination With xxxxxxxxxx In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To xxxxxxxxxx

2015

A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination XX/XXXX/XX with the fixed dose dual combinations of XX/XX and XXXX/XX, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Global Anticoagulant Registry in the FIELD (GARFIELD) observing treatment and outcomes in patients with treated acute Venous Thromboembolic (VTE) Events in the real world.

A Randomized, Open-Label, Daily Dose, Two-sequence, Two-way Crossover Pharmacodynamic and Pharmacokinetic Study of xxxxx xx Capsules and Commercial xxxxx Tablets in Self identified Black Patients, who are Slow Acetylators, with Heart Failure

A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder (OAB)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of xxxxxxxx for the Treatment of Anaemia in Chronic Kidney Disease Patients not on Dialysis

A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of xxxxxxxxxxxx in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of xxxxxxxxxxx (xx-xxxx/xx-xxxxxxxx) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

A multi-center, randomized, double-blind, double-dummy, active controlled, 2-period cross-over study to assess the efficacy, safety and tolerability of xxxxxxxxx xxxxxxx/xxxxxxxxxxxx bromide compared to xxxxxxxxxx xxxxxxx/xxxxxxxxx in COPD patients with moderate to severe airflow limitation

A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of xxxxx Relative to xxxxx and xxxxx on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

A randomized, open-label, parallel-group real world pragmatic trial to assess the clinical and health outcomes of xxxxxx® compared to commercially available basal insulins for initiation of therapy in insulin naive patients with uncontrolled type 2 diabetes mellitus

Efficacy, Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection